Cargando…
Methyl 1-[(6-methoxy-5-methylpyrimidin-4-yl)methyl]-1H-benzo[d]imidazole-7-carboxylate: a combined X-ray and DFT study
The title compound, C(16)H(16)N(4)O(3), was obtained as a side product during the synthesis of the previously reported antitubercular agent N-(2-fluoroethyl)-1-[(6-methoxy-5-methylpyrimidin-4-yl)methyl]-1H-benzo[d]imidazole-4-carboxamide and structurally characterized by X-ray crystallography...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
International Union of Crystallography
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9912325/ https://www.ncbi.nlm.nih.gov/pubmed/36794056 http://dx.doi.org/10.1107/S2414314623000251 |
Sumario: | The title compound, C(16)H(16)N(4)O(3), was obtained as a side product during the synthesis of the previously reported antitubercular agent N-(2-fluoroethyl)-1-[(6-methoxy-5-methylpyrimidin-4-yl)methyl]-1H-benzo[d]imidazole-4-carboxamide and structurally characterized by X-ray crystallography and computational methods. In the crystal (space group P2(1)/n, Z = 4), the title compound adopts a twisted conformation with a dihedral angle between the benzimidazole and pyrimidine mean planes of 84.11 (3)°. The carboxylate group and the 5-methyl group on the pyrimidine ring exhibit partial disorder. The DFT-optimized molecular structure resembles the structure of the minor component in the crystal. [Image: see text] |
---|